Geographic Disparities in Incidence and All Cause Mortality Among Patients with Hepatocellular Carcinoma
AASLD LiverLearning®, Ricardo Franco, 144645
Trends and Determinants in Mortality after Cirrhosis-Related Admissions over a Decade
AASLD LiverLearning®, Aylin Tansel, 144646
Safety and Efficacy of Sofosbuvir in Combination with Daclatasvir or Simeprevir With or Without Ribavirin in the Treatment of Chronic HCV Genotype 4-infected Patients: A Real World Experience.
AASLD LiverLearning®, Ali Albenmousa, 144902
Primary Care and Hepatology Provider Attitudes Towards Hepatitis C Treatment Candidacy and Adherence
AASLD LiverLearning®, Shari Rogal, 144647
Predictors of Sustained Virologic Response in 21,242 Genotype 1 Patients Treated with Ledipasvir/Sofosbuvir±Ribavirin or Ombitasvir/Paritaprevir/Ritonavir+Dasabuvir±Ribavirin in Routine Medical Practice
AASLD LiverLearning®, Lisa Backus, 144903
Reduction in hemoglobin and Increased lab encounters among Veterans treated with ledipasvir-sofosbuvir combined with ribavirin
AASLD LiverLearning®, Lydia Tang, 144904
Effect of interferon free antiviral treatment on lipid metabolism, lipid oxidation and insulin-resistance in chronic hepatitis C patients with advanced liver disease
AASLD LiverLearning®, Elisa Biliotti, 144905
Alcohol use disorder among chronic hepatitis C patients: prevalence and treatment outcome, CHeCS, 2006-2013
AASLD LiverLearning®, Eyasu Teshale, 144661
Balloon Tamponade Utilization is an Indicator of Quality in the Management of Acute Variceal Hemorrhage
AASLD LiverLearning®, Elliot Tapper, 144662
Efficacy and safety of direct acting antiviral(s) (DAA) containing regimens in the treatment of chronic hepatitis C (CHC) patients with genotype 3. A real life experience
AASLD LiverLearning®, John Koskinas, 144918
High incidence of significant liver fibrosis among HBeAg-positive patients with low levels of ALT
AASLD LiverLearning®, Milan Sonneveld, 144663
Generic versus brand Sofosbuvir-based therapy: safety and efficay,real life data
AASLD LiverLearning®, Moutaz Derbala, 144919
Clinically Significant Changes in Heart Rate and Adverse Events are Not Observed in Clinical Trial Patients Receiving SOF-Based Regimens While On Beta-Blockers
AASLD LiverLearning®, Curtis Cooper, 144920
Increase in 10-Year Framingham Cardiovascular Risk Following HCV Eradication with DAA-Based Therapy in HIV/HCV-Coinfected Patients
AASLD LiverLearning®, Teresa Aldámiz-Echevarría, 144921
Quantifying perinatal transmission of Hepatitis B viral quasispecies by tag linkage deep sequencing
AASLD LiverLearning®, XIUMEI CHI, 144677
Development and performance of prototype serologic and molecular tests for the detection and quantification of the hepatitis Delta virus on the Abbott ARCHITECT and m2000 instruments.
AASLD LiverLearning®, Gavin Cloherty, 144678
Elevated Ferritin is Associated with Increased Mortality in Patients with Cirrhosis Admitted to Intensive Care Units
AASLD LiverLearning®, Christina Lindenmeyer, 144934
Glucocorticoid Pulse Therapy and Hepatitis B Flares: A Retrospective Cohort Study
AASLD LiverLearning®, Sheng-Shun Yang, 144679
Successful Outcomes of Fecal Microbiota Transplantation in Patients with Chronic Liver Disease
AASLD LiverLearning®, Alireza Meighani, 144935
Quick Sequential Organ Failure Assessment (qSOFA) is a Better Predictor for Intensive Care Admission than Systemic Inflammatory Response Syndrome (SIRS) For Patients with Cirrhosis
AASLD LiverLearning®, Kavish Patidar, 144936
Does the presence of cirrhosis influence on the mortality rate in patients with acute on chronic liver failure?
AASLD LiverLearning®, Sombat Treeprasertsuk, 144937
A brief introduction to the community-based comprehensive management of Hepatitis B demonstration project in Jiangsu province, china
AASLD LiverLearning®, Xiangjun Zhai, 144693
Prevention system of acute exacerbation of chronic hepatitis B infection in patients receiving chemotherapy and immunosuppressive therapy in Miyazaki, Japan
AASLD LiverLearning®, Yuuri Yamada, 144694
Predicting Mortality in Patients with Cirrhosis Admitted to Intensive Care Units: A Novel Prognostic Model
AASLD LiverLearning®, Christina Lindenmeyer, 144950
Preventing mother to child transmission of HBV in an ethnically diverse South London population: an effective multidisciplinary clinical pathway
AASLD LiverLearning®, Ivana Carey, 144695
Natural Course and Outcome in ACLF is Dependent upon the Etiology of Acute Hepatic Insults: Analysis of 368 patients.
AASLD LiverLearning®, . Shalimar, 144951
NMR based urinary profiling of Lactulose/Mannitol ratio to compare the intestinal permeability in cirrhosis, acute on chronic liver failure (ACLF) patients and normal controls
AASLD LiverLearning®, Gaurav Pande, 144952
Over One Third of Chronic Hepatitis B Virus Patients Have Concurrent Nonalcoholic Fatty Liver Disease, With the Highest Risk Among Non-Asians and Patients with Metabolic Risk Factors
AASLD LiverLearning®, Wada Sharma, 144710
Targeted heart rate reduction using carvedilol± ivabradine improves left ventricular diastolic dysfunction, clinical progression and survival in cirrhosis
AASLD LiverLearning®, Madhumita Premkumar, 144966
Racial disparity in the Prevalence of Hepatitis B Virus (HBV) Infection in the United States: Results from the National Health and Nutrition Examination Survey 2011-2014
AASLD LiverLearning®, Hyunseok Kim, 144711
Association between adrenal insufficiency and renal dysfunction in cirrhosis
AASLD LiverLearning®, Eleni Theocharidou, 144967
Subcirrhotic liver stiffness by transient elastography correlates with lower risk of hepatocellular carcinoma in patients with HBV-related cirrhosis
AASLD LiverLearning®, Mi Young Jeon, 144712
Comparison of prognostic efficacy of acute kidney injury criteria in patients with liver cirrhosis
AASLD LiverLearning®, TAE HYUNG KIM, 144968
Unexplained chronic liver disease in Eastern Ethiopia: a cross-sectional study
AASLD LiverLearning®, Stian M S Orlien, 144726
Development of a novel staging model for cirrhosis outcome using the Nationwide Inpatient Sample
AASLD LiverLearning®, Mona Haj, 144982
Validation of a diagnostic strategy combining the transient elastography liver stiffness value and enhanced liver fibrosis test to assess the fibrotic burden in patients with chronic hepatitis B
AASLD LiverLearning®, Ja Yoon Heo, 144727
Aquaporin-2 (AQP2) excretion in hospitalized patients with cirrhosis: relation to development of renal insufficiency and mortality.
AASLD LiverLearning®, Troels Busk, 144983
Profile of viral, biochemical and non-invasive fibrosis markers in a cohort of inactive European hepatitis B (HBV) carriers: 3 years follow-up of a prospective longitudinal study (ALBATROS Study)
AASLD LiverLearning®, Viola Knop, 144728
Urine and Serum Biomarkers in Predicting Recovery of Renal Function After Liver Transplantation Among Patients with Cirrhosis and Pre-transplant Renal insufficiency: A Prospective Study
AASLD LiverLearning®, Ashwani Singal, 144984
HBV Core Assembly Modulators Block Antigen Production when Present during Infection, but not during Persistent Infection
AASLD LiverLearning®, Angela Lam, 144742
Changes in Antimicrobial Susceptibility of Fecal Bacteria During Rifaximin Treatment for the Prevention of Overt Hepatic Encephalopathy (HE) Recurrence
AASLD LiverLearning®, Herbert DuPont, 144998
Safety and Efficacy of GS-9620 in Virally-Suppressed Patients with Chronic Hepatitis B
AASLD LiverLearning®, Harry Janssen, 144743
Hypoxia leads to ligand independent activation and nuclear translocation of the mineralocorticoid receptor (MR) in hepatocytes - a mechanism explaining lower hepatic MR expression in cirrhosis
AASLD LiverLearning®, Alexander Zipprich, 144999
Features of the metabolic syndrome are associated with lack of serum ALT normalization during therapy for chronic hepatitis B
AASLD LiverLearning®, Scott Fung, 144744
Hyperammonemia induces a novel maladaptive cellular stress response and impaired proteostasis resulting in sarcopenia.
AASLD LiverLearning®, Srinivasan Dasarathy, 145000
Evaluation of antiviral effects of a novel site-specific pegylated interferon beta using humanized mouse model
AASLD LiverLearning®, Masataka Tsuge, 144758
The risk of hepatocellular carcinoma (HCC) is decreasing after the first 5 years of entecavir (ETV) or tenofovir (TDF) therapy in Caucasian chronic hepatitis B (CHB) patients
AASLD LiverLearning®, George Papatheodoridis, 144759
TG1050, an HBV-targeted immunotherapeutics, efficiently decreases HBV viremia and antigenemia in a preclinical model; a meta-analysis and the determination of the involvement of CD4 and CD8 T cells
AASLD LiverLearning®, Roland Kratzer, 144760
Predictors of HBeAg loss in HBeAg-positive patients with chronic hepatitis B during treatment with tenofovir alafenamide or tenofovir disoproxil fumarate
AASLD LiverLearning®, Calvin Pan, 144774
Pharmacokinetics (PK) and PK modeling of the first-in-class HBV core inhibitor NVR 3-778 dosed once- (QD) or twice daily (BD) in healthy volunteers (HVs) and HBeAg-positive patients with chronic HBV infection (CHBV)
AASLD LiverLearning®, Thomas Kakuda, 144775
Risk of Renal Function Impairment Among Cancer Patients Treated With Tenofovir or Entecavir for HBV Prophylaxis During Chemotherapy
AASLD LiverLearning®, Yi-Hsiang Huang, 144776
Predictors of non-adherence to HBV anti-viral therapy
AASLD LiverLearning®, Suzanne Sheppard-Law, 144533
The Complex Process of Hepatitis C Direct Acting (DAA) Viral Therapy Drug Approval: an breakdown of the process in a community practice setting by insurance payer
AASLD LiverLearning®, Susan Lee, 144534
Polyethylenimines (PEI) polymer functionalized with L-mannose moieties inhibits hepatitis B virus (HBV) entry into HepG2-hNTCP cells with negligible cellular toxicity.
AASLD LiverLearning®, Guan Huei Lee, 144790
The Effect of a 12-month Weight Loss Program on Non-alcoholic Fatty Liver Disease in Obese Patients
AASLD LiverLearning®, Anna Hefner, 144535
Nucleos(t)ide Analogue Discontinuation is not Associated with Increased Rates of HBsAg Loss in Chronic Hepatitis B
AASLD LiverLearning®, Heng Chi, 144791
HBV RNA and HBV core-related antigen (HBcrAg) are early serum markers for HBeAg seroconversion in treatment experienced patients receiving tenofovir disoproxil fumarate (TDF)-containing regimens
AASLD LiverLearning®, Florian van Boemmel, 144792
Minimal Changes in Urine Markers of Tubular Dysfunction in CHB Patients Receiving Tenofovir alafenamide (TAF) compared with Tenofovir Disoproxil Fumarate (TDF)
AASLD LiverLearning®, Young-Suk Lim, 144793
Black and Latino Race/Ethnicity Increase the Risk of Hospitalization for Autoimmune Hepatitis in the United States
AASLD LiverLearning®, Jason Wen, 144549
Balance between exhausted regulatory T cells and CD161+ NK cells is crucial in acute AIH pathogenesis
AASLD LiverLearning®, Ye Htun Oo, 144550
Experience with Direct Antiviral Agents in Hispanic patients with Chronic Hepatitis C genotype 1 at the Veteran Affairs Caribbean Healthcare System in San Juan
AASLD LiverLearning®, Arnaldo L Freire-Perez, 144806
Regional and National understanding of IgG-related disease (IgG4-RD) in the UK- strategic implications in testing and case-finding
AASLD LiverLearning®, Marinos Pericleous, 144551
The Effect of Gastric Acid Suppression on Ledipasivir-Sofosbuvir Effectiveness in Chronic Hepatitis C Infection.
AASLD LiverLearning®, Glen Lutchman, 144807
Using telemedicine to monitor patients on treatment of HCV infection in prison
AASLD LiverLearning®, Javier Crespo, 144808
Treatment uptake for chronic hepatitis C in Australia following universal access to interferon-free treatments
AASLD LiverLearning®, Behzad Hajarizadeh, 144809
The I148M PNPLA3 variant is a novel key player modulating the pro-fibrogenic phenotype of human hepatic stellate cells
AASLD LiverLearning®, Francesca Bruschi, 144565
Impact of the combination of Farnesoid X receptor agonist and angiotensin-II type1 receptor blocker on hepatic fibrogenesis in the rat model of nonalcoholic steatohepatitis
AASLD LiverLearning®, Tadashi Namisaki, 144566
Efficacy and safety of DAA regimens in HCV genotype 1b patients with compensated cirrhosis: data of RESIST-HCV Cohort
AASLD LiverLearning®, Salvatore Madonia, 144822
High mobility group box-1 participates in the pathogenesis of liver fibrosis
AASLD LiverLearning®, Xiaodong Ge, 144567
Sofosbuvir-Based All-Oral Regimens for Patients with Chronic Hepatitis C Genotype 3 Infection: Integrated Analysis of Five Clinical Studies
AASLD LiverLearning®, Graham R. Foster, 144823
Virological response to ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin in 150 patients with mixed cryoglobulinaemia and HCV infection
AASLD LiverLearning®, Liana Gheorghe, 144824
Treatment of Patients with Hepatitis C Virus infection (Genotype 4) with Ledipasvir-Sofosbuvir in the liver transplant setting
AASLD LiverLearning®, Faisal Abaalkhail, 144825
The Expression of MicroRNA-101 in Hepatic Cirrhosis - Hepatocellular Carcinoma and Its Effects on Hepatic Fibrosis
AASLD LiverLearning®, Chenghai Liu, 144581
Hedgehog-responsive Myofibroblasts activate Yes-associated Protein (Yap) 1 and Promote TGFb-Signaling to Induce Epithelial-Mesenchymal Transitions in Hepatocytes during Murine Liver Regeneration
AASLD LiverLearning®, Anna Mae Diehl, 144582
The Impact of Hepatitis C Virus Cure on Progression of Renal Disease
AASLD LiverLearning®, Carla Rodriguez, 144838
MMP9 is a potential mediator of TWEAK-Fn14 signaling in a rodent model of acute alcoholic steatohepatitis
AASLD LiverLearning®, Anna Mae Diehl, 144583
High efficacy of hepatitis C re-treatment strategies after protease inhibitors failure in real-life settings
AASLD LiverLearning®, Valeria Cento, 144839
Effect and safety of daclatasvir and asunaprevir combination therapy for chronic hepatitis HCV genotype 1b infection in patients with severe fibrosis; From real world data.
AASLD LiverLearning®, Masatoshi Ishigami, 144840
Effectiveness of Sofosbuvir/Ledipasvir HCV Treatment Regimens in a Community Setting
AASLD LiverLearning®, T Craig Cheetham, 144841
The Usefullness of WFA+-M2BP for predicting gastroesophageal varices and liver related events in HCV-related cirrhosis.
AASLD LiverLearning®, Tsuguru Hayashi, 144597
Long-term proton pump inhibitor therapy improves survival in liver cirrhosis patients with variceal bleeding: A single center prospective study
AASLD LiverLearning®, Sang Hoon Kwon, 144598
The safety, tolerability and efficacy of paritaprevir/ritonavir/ombitasvir and dasabuvir with ribavirin in a large real life multi-center cohort of genotype 1b HCV infected patients with liver cirrhosis at the edge of decompensation
AASLD LiverLearning®, Ana Maria Singeap, 144854
Screening of oesophagogastric varices in virus-related compensated advanced chronic liver disease: Baveno VI criteria and beyond
AASLD LiverLearning®, Roberta D Ambrosio, 144599
Efficacy and Safety of oral DAAs HCV therapy in the Elderly
AASLD LiverLearning®, Francesco P Russo, 144855
Interferon-free therapies on routine medical practice for the treatment of hepatitis C infection in difficult to treat HIV coinfected patients: results of the multicentric COINFECOVA-2 study.
AASLD LiverLearning®, Carlos Minguez, 144856
Treatment of Chronic Hepatitis C Genotype 4 -infected Patients with Ombitasvir/Paritaprevir/Ritonavir Plus Ribavirin: Real Life Data From Saudi Arabia
AASLD LiverLearning®, khalid alswat, 144857
Cost and utility estimates for patients at different stages in the natural history of Primary Biliary Cirrhosis (PBC) from the UK-PBC Cohort
AASLD LiverLearning®, Stephen Rice, 144613
Cost, Value and Clinical Consequences Associated with Treatment Restrictions for Hepatitis C-infected Medicaid Beneficiaries
AASLD LiverLearning®, Mai Pho, 144614
Non-adherence is the most important risk factor for ledipasvir/sofosbuvir HCV treatment failure in the real world.
AASLD LiverLearning®, Dost Sarpel, 144870
Hepatitis C Treatment in United States Prisons Prevents Transmission and is Cost-Saving for the Society
AASLD LiverLearning®, Jagpreet Chhatwal, 144615
Dynamics of AFP in cirrhotic patients with virological response following 3D therapy and severe necro-inflammation at Fibromax
AASLD LiverLearning®, Maria C. Speranta Iacob, 144871
DAA-Treatment of HCV-infected patients on Opioid Substitution Therapy (OST): does the clinical setting matter? Data from the German Hepatitis C-Registry (DHC-R)
AASLD LiverLearning®, Stefan Christensen, 144872
Safety and efficacy of regimens including direct acting antivirals (DAAs) in chronic hepatitis C (CHC) patients over the age of 70 years
AASLD LiverLearning®, Emmanouil Sinakos, 144873
Trends Comparing Alcohol Related Liver Disease in Women and Men in the United States from 2006 and 2013: A Nationwide Analysis
AASLD LiverLearning®, Lauren Stemboroski, 144629
Socioeconomic and Survival Differences among Minorities With Hepatocellular Carcinoma in Florida
AASLD LiverLearning®, Patricia Jones, 144630
Effectiveness and safety of direct-acting antiviral therapies (DAA) in cirrhotic HCV monoinfected and HIV/HCV coinfected patient
AASLD LiverLearning®, Pilar Carmona, 144886
Hospital re-admission predicts 5-year survival in patients with cirrhosis - A population-based study.
AASLD LiverLearning®, Jennifer Flemming, 144631
Treatment of US Veterans with hepatitis C virus (HCV) genotype (GT) 1 infection: effectiveness of Ledipasvir/Sofosbuvir (Harvoni®) and Ombitasvir/Paritavir/Ritonavir/Dasubuvir (Viekira Pak®) regimens.
AASLD LiverLearning®, Danny Issa, 144887
Sofosbuvir/Ledipasvir in the Treatment of Early HCV Infection in HIV-infected Men
AASLD LiverLearning®, Daniel Fierer, 144888
Primary care based model using patient navigators highly successful in obtaining HCV medications for inner-city HCV-monoinfected patients
AASLD LiverLearning®, Wilma Toribio, 144889